<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:contributor>Megan E. Griffiths</dc:contributor>
  <dc:contributor>Rustom Antia</dc:contributor>
  <dc:contributor>Laura M. Bergner</dc:contributor>
  <dc:contributor>Peter Bowman</dc:contributor>
  <dc:contributor>Maria Vitoria dos Santos de Moraes</dc:contributor>
  <dc:contributor>Kevin Esvelt</dc:contributor>
  <dc:contributor>Mike Famulare</dc:contributor>
  <dc:contributor>Amy T. Gilbert</dc:contributor>
  <dc:contributor>Biao He</dc:contributor>
  <dc:contributor>Michael A. Jarvis</dc:contributor>
  <dc:contributor>David A. Kennedy</dc:contributor>
  <dc:contributor>Jennifer Kuzma</dc:contributor>
  <dc:contributor>Carolyne Nasimiyu Wanyonyi</dc:contributor>
  <dc:contributor>Christopher Remien</dc:contributor>
  <dc:contributor>Kyle Rosenke</dc:contributor>
  <dc:contributor>Tonie E. Rocke</dc:contributor>
  <dc:contributor>Courtney Schreiner</dc:contributor>
  <dc:contributor>Justin Sheen</dc:contributor>
  <dc:contributor>David Simons</dc:contributor>
  <dc:contributor>Ivet A. Yordanova</dc:contributor>
  <dc:contributor>James J. Bull</dc:contributor>
  <dc:contributor>Scott L. Nuismer</dc:contributor>
  <dc:creator>Daniel G. Streicker</dc:creator>
  <dc:date>2024</dc:date>
  <dc:description>&lt;div id="abstracts" data-extent="frontmatter"&gt;&lt;div class="core-container"&gt;&lt;div&gt;Many emerging and reemerging pathogens originate from wildlife, but nearly all wild species are unreachable using conventional vaccination, which requires capture of and vaccine administration to individual animals. By enabling immunization at scales sufficient to interrupt pathogen transmission, transmissible vaccines (TVs) that spread themselves through wildlife populations by infectious processes could potentially transform the management of otherwise intractable challenges to public health, wildlife conservation, and animal welfare. However, generating TVs likely requires modifying viruses that would be intended to spread in nature, which raises concerns ranging from technical feasibility, to safety and security risks, to regulatory uncertainties (&lt;a id="body-ref-R1" href="https://www.science.org/doi/10.1126/science.adn3231#core-R1" data-xml-rid="R1" aria-label="Reference 1" data-mce-href="https://www.science.org/doi/10.1126/science.adn3231#core-R1"&gt;&lt;i&gt;1&lt;/i&gt;&lt;/a&gt;,&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;a id="body-ref-R2" href="https://www.science.org/doi/10.1126/science.adn3231#core-R2" data-xml-rid="R2" aria-label="Reference 2" data-mce-href="https://www.science.org/doi/10.1126/science.adn3231#core-R2"&gt;&lt;i&gt;2&lt;/i&gt;&lt;/a&gt;). We propose a series of commitments and strategies for vaccine development—beginning with a priori decisions on vaccine design and continuing through to stakeholder codevelopment [see supplementary materials (SM)]—that we believe increase the likelihood that the potential risks of vaccine transmission are outweighed by benefits to conservation, animal welfare, and zoonosis prevention.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>10.1126/science.adn3231</dc:identifier>
  <dc:language>en</dc:language>
  <dc:publisher>AAAS</dc:publisher>
  <dc:title>Developing transmissible vaccines for animal infections</dc:title>
  <dc:type>article</dc:type>
</oai_dc:dc>